Tomas Vasiliauskas, MD
Cardiovascular Disease · Santa Rosa, CANPI 1073612529
Payments from drug & device makers
Across 230 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$1K
- Edwards Lifesciences$851
- Amgen$413
- Esperion Therapeutics, Inc.$393
- E.r. Squibb & Sons, L.L.C.$365
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,792100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $1,703 |
| Medtronic | 20 | $1,044 |
| Edwards Lifesciences | 7 | $851 |
| Amgen | 19 | $413 |
| Esperion Therapeutics, Inc. | 13 | $393 |
| E.r. Squibb & Sons, L.L.C. | 13 | $365 |
| Boston Scientific | 11 | $352 |
| Merck | 11 | $266 |
| Boehringer Ingelheim | 10 | $230 |
| Novartis | 11 | $226 |
| Johnson & Johnson | 14 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $210 |
| Actelion Pharmaceuticals US, Inc. | 7 | $189 |
| United Therapeutics Corporation | 7 | $175 |
| Atricure, Inc. | 1 | $145 |
| Pfizer | 6 | $117 |
| Abiomed | 3 | $87 |
| AstraZeneca | 5 | $85 |
| Bayer | 3 | $85 |
| Impulse Dynamics (USA) Inc. | 2 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Heartflow, Inc. | 2 | $65 |
| Astellas Pharma US Inc | 3 | $51 |
| Irhythm Technologies, Inc. | 3 | $45 |
| Preventice Services, LLC | 1 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Bridgebio Pharma, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Philips North America LLC | 1 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Terumo Medical Corporation | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$639
- Micra$589
- MITRIS RESILIA Mitral Valve$254
- CardioMEMS HF System$246
- Reveal LINQ$167
- CAMZYOS$149
- SYNERGY ABLATION SYSTEM$145
- ATRICLIP LAA EXCLUSION SYSTEM$145
- INSPIRIS RESILIA aortic valve$135
- MitraClip$125
- MitraClip System$124
- NEXLIZET$121
- NEXLETOL$121
How this compares
$7,792 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $473,084 |
| XareltoRivaroxaban | 114 | $153,197 |
| Repatha SureclickEvolocumab | 175 | $131,499 |
| EntrestoSacubitril/Valsartan | 77 | $121,974 |
| JardianceEmpagliflozin | 17 | $22,773 |
| Praluent PenAlirocumab | 14 | $11,231 |
| Atorvastatin Calcium | 503 | $5,194 |
| Metoprolol Succinate | 289 | $4,670 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 103 | $4,255 |
| Valsartan | 112 | $3,603 |
| Rosuvastatin Calcium | 191 | $3,582 |
| Losartan Potassium | 254 | $3,381 |
| Amiodarone Hcl | 80 | $3,268 |
| Furosemide | 289 | $2,477 |
| Potassium Chloride | 59 | $2,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $473,084357 claims |
| Johnson & JohnsonXarelto | $216 | $153,197114 claims |
| NovartisEntresto | $226 | $121,97477 claims |
| Boehringer IngelheimJardiance | $230 | $22,77317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Santa Rosa
- Stephen HalpernSanta Rosa$1.2M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.